Rebuzzi, Sara Elena
Fornarini, Giuseppe
Signori, Alessio
Buti, Sebastiano
Procopio, Giuseppe
De Giorgi, Ugo
Pignata, Sandro
Naglieri, Emanuele
Maruzzo, Marco
Banna, Giuseppe Luigi
Rescigno, Pasquale
Messina, Carlo
Mattana, Alvise
Basso, Umberto
Bimbatti, Davide
Article History
Received: 7 October 2023
Accepted: 29 April 2024
First Online: 24 June 2024
Declarations
:
: The study protocol was approved by the Ethics Committee of Istituto Oncologico Veneto IOV IRCCS of Padua on the 1st of June 2023 (Registrational number: CESC IOV 2023-78).
: Not applicable.
: SER received honoraria as speaker at scientific events and travel accommodation from BMS, Amgen, GSK, Ipsen, Astellas, Janssen and MSD. GF services advisory boards for Astellas, Janssen, Pfizer, Bayer, MSD, Merck and received travel accommodation from Astellas, Janssen, Bayer. DB received honoraria as advisory role by Ipsen, Astellas, Janssen, Novartis, BMS, MSD, Pfizer, Merck and travel accommodation from Ipsen, Janssen, MSD, Merck. UB received honoraria as advisory role by BMS, Novartis, research funding from Ipsen and travel accommodation from BMS, Janssen, Astellas, Ipsen, MSD, Merck, Pfizer, Bayer. SB received honoraria as speaker at scientific events and advisory role by BMS, Pfizer, MSD, Ipsen, Roche, Eli Lilly, AstraZeneca, Pierre-Fabre, Novartis, Merck, Gentili, Astellas. GP services advisory boards/consulting for Astellas, AstraZeneca, BMS, Janssen, IPSEN, Merk, MSD, Novartis, Pfizer. UDG services as advisory/board member of Astellas, Bayer, BMS, IPSEN, Janssen, Merck, Pfizer, Sanofi, received research grant/funding to the institution from AstraZeneca, Roche, Sanofi and travel/accommodations/expenses from BMS, IPSEN, Janssen, Pfizer. GLB reports personal fees from AstraZeneca and Astellas for speaker bureau. PR services advisory boards for MSD, AstraZeneca and Janssen. The other authors have no conflicts of interest to disclose. The study is conducted in accordance with the Good Clinical Practice (GCP) guidelines, the Helsinki Declaration and the local regulatory requirements for medical research involving human subjects. The documented approval by the local Ethics Committee will be required for each center as a condition for center recruitment. Investigators must inform the patients about the nature, objectives and aims of the study. All patients alive provide written informed consent before the inclusion into the study. The other authors have no conflicts of interest to disclose.